AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 0.22 |
Market Cap | 6.39M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -3.07 |
PE Ratio (ttm) | -0.08 |
Forward PE | n/a |
Analyst | Hold |
Ask | 0.24 |
Volume | 1,669,652 |
Avg. Volume (20D) | 9,687,409 |
Open | 0.23 |
Previous Close | 0.24 |
Day's Range | 0.21 - 0.25 |
52-Week Range | 0.18 - 7.96 |
Beta | undefined |
About SYRS
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acu...
Analyst Forecast
According to 5 analyst ratings, the average rating for SYRS stock is "Hold." The 12-month stock price forecast is $3, which is an increase of 1159.45% from the latest price.
Next Earnings Release
Analysts project revenue of $450.00K, reflecting a 16.28% YoY growth and earnings per share of -0.74, making a -66.06% decrease YoY.
2 months ago · seekingalpha.com
Syros Pharmaceuticals, Inc (SYRS) Q3 2024 Earnings Call TranscriptSyros Pharmaceuticals, Inc (NASDAQ:SYRS ) Q3 2024 Earnings Conference Call October 31, 2024 8:30 AM ET Company Participants Karen Hunady - Director of Investor Relations and Corporate Communications C...
2 months ago · businesswire.com
Syros Reports Third Quarter 2024 Financial Results and Provides a Business UpdateCAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancie...
2 months ago · businesswire.com
Syros to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies...